Evidence map›Paper›PMID 26222847›Full record

Observational studyMedicine2015

Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.

Luca Cantarini, Marta Fabbroni, Rosaria Talarico, Luisa Costa, Francesco Caso, Gian Luca Cuneo, Bruno Frediani, Gabriele Faralli, Antonio Vitale, Maria Giuseppina Brizi and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. The role of ixekizumab in non-radiographic axial spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2021
    Article
  5. Review
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Luca CantariniFrom the Rheumatology Unit (LC, MF, BF, AV, MGB, MG), Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena; Rheumatology Unit (RT), Department of Clinical and Experimental Medicine, University of Pisa, Pisa; Rheumatology Research Unit (LC), Department of Clinical and Experimental Medicine, University Federico II, Naples; Rheumatology Unit (FC), Department of Medicine DIMED, University of Padua, Padua; Neuroradiology Unit (GLC), S. Donato Hospital, Cardiovascular and Neurologic Department, Arezzo; Radiology Unit (GF), S. Donato Hospital, Department of Diagnostic and Clinical Pathology, Arezzo; and Rheumatology Unit (LS), Department of Internal Medicine, Arezzo, Italy.
Marta Fabbroni
Rosaria Talarico
Luisa Costa
Francesco Caso
Gian Luca Cuneo
Bruno Frediani
Gabriele Faralli
Antonio Vitale
Maria Giuseppina Brizi
Luciano Sabadini
Mauro Galeazzi
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary aim of the study was to evaluate the long-term effectiveness of adalimumab (ADA) in a cohort of non-radiographic axial spondyloarthritis (nr-axSpA), and the secondary aims were to identify predictive factors of response and evaluate radiological progression.We evaluated 37 patients (male/female: 12/25; mean age 49 ± 14; mean disease duration: 6.3 ± 5.8) with active nr-axSpA (Assessment of SpondyloArthritis International Society criteria), despite the treatment with ≥1 nonsteroidal anti-inflammatory drug for at least 3 months, initiating the treatment with ADA 40 mg every other week. Patients were treated for 24 months, and evaluated at baseline, 6, 12, and 24 months. Outcome measures included Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index. Radiograph of the spine and sacroiliac joints and magnetic resonance of the sacroiliac joints were performed at baseline and according to the standard of assessment for the disease.The proportion of patients that achieved a BASDAI50 response at 6, 12 and 24 months was 51.3%, 70.3%, and 76.8%, respectively. Treatment was well tolerated with no unexpected adverse events and/or serious adverse events. All patients remained on treatment for 2 years, with a good compliance. We did not identify any predictive factor of response to therapy. Moreover, modified Stoke Ankylosing Spondylitis Spine Score and Spondyloarthritis Research Consortium of Canada scores showed a trend of improvement during the study period.ADA was effective on clinical and radiological outcomes at 2-year follow-up; thus, early treatment with ADA may prevent radiographic damage and be associated with low disease activity or remission. Moreover, data from this cohort study have confirmed safety and tolerability profile of ADA in nr-axSpA in the long term.

Indexed as

AdalimumabAdultAgedAntibodies, Monoclonal, HumanizedAntirheumatic AgentsDisease ProgressionDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansLumbar VertebraeMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexAdalimumabAntibodies, Monoclonal, HumanizedAntirheumatic AgentsTumor Necrosis Factor-alpha

Identifiers

PMID26222847
PMCPMC4554135
OpenAlexW2322142470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.